Oxitope is dedicated to the development of antibody-based medicines for the treatment of diseases caused by oxidative stress, company officials said.

Co-founders Drs. Joe Witztum and Sam Tsimikas are professors at the University of California, San Diego. Witztum and Tsimikas have investigated how oxidative stress can induce the formation of oxidation-specific epitopes (OSEs). OSEs are believed to be key drivers of unhealthy aging and can play a key role in inflammatory, cardiovascular, and fibrotic diseases.

Oxitope aims to provide therapeutics to treat a range of cardiovascular, inflammatory, and fibrotic indications, the company said.

Alligator Bioscience, MacroGenics to develop novel immunotherapy
Alligator Bioscience has entered a joint research collaboration with MacroGenics focused on the development and commercialization of monoclonal antibody-based...

What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries...

Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...

Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly...